

4 June 2024

AHAM Capital Launches Biotechnology Fund

The new fund offering by the company allows investors to gain diversified exposure to cutting-edge innovation in the biotechnology space

KUALA LUMPUR – AHAM Asset Management Berhad ("AHAM Capital" or "the Company") announced today the launch of the AHAM World Series – Biotechnology Fund ("the Fund"). The Fund is a wholesale feeder growth fund that provides investors access to the burgeoning opportunities within the biotechnology investment universe.

The Fund will primarily invest in the Janus Henderson Horizon Biotechnology Fund ("Target Fund"), managed by Janus Henderson ("Target Fund Manager"). To achieve its investment objective, the Fund will allocate a minimum of 85% of its net asset value (NAV) to the Target Fund and a maximum of 15% to money market instruments, deposits, and/or cash.

Anton Tan, Chief Officer of Product Solutions & Customer Experience at AHAM Capital said, "Biotechnology companies are at the forefront of scientific innovation, rapidly enhancing our genetic understanding to develop new treatment for major diseases. Over the past decade, we have seen significant improvements in scientific productivity, with the number of drugs receiving FDA approval doubling from 121 to 243 in the past 20 years¹.

"Healthcare spending is poised to increase driven by a demographic shift in the US, coupled with aging populations and globalisation. These long-term secular forces create an attractive fundamental backdrop for biotechnology investments. Despite experiencing its worst drawdown on record, the biotech sector is currently trading at a substantial discount to the broader market, presenting a unique 'innovation on sale' opportunity.

“Furthermore, the biotechnology sector offers a broad spectrum of opportunities across small and large-cap companies, providing diversification for investors' portfolios. By positioning themselves in this healthcare revolution, investors can benefit from the continued breakthroughs in biotechnology,” Anton adds.

On outlook for the sector **Andy Acker, Portfolio Manager of Janus Henderson** says, “Biotechnology is currently undergoing unprecedented levels of innovation, thanks to dramatic improvements in life science tools, genetic engineering, and new modalities for treating human diseases such as cancer, autoimmune disease, and rare genetic conditions. These advancements are unearthing opportunities for investors to identify the next blockbuster (billion dollar) therapies and generate alpha for clients.

“At the same time, success in biotech is highly binary in nature, and the disparity between winners and losers are very pronounced. To mitigate this, the biotechnology team at Janus Henderson combine investment experience, scientific expertise, and proprietary statistical models to estimate the probability of success for drugs in clinical development. The team also focuses on the perspectives of physicians, patients, and payers to evaluate the commercial prospects for new therapies to pursue the best investment outcomes for our clients.”

The Fund is suitable for sophisticated investors seeking capital appreciation with a medium to long-term investment horizon. The Base Currency of the Fund is in USD and is available in three currency classes namely, USD Class, MYR Class, and MYR Hedged-Class. The minimum investment amount is \$10,000 for the USD Class and \$30,000 for the MYR Class and MYR Hedged-Class.

Investors are advised to read and understand the contents of the Fund's Product Highlights Sheet and Information Memorandum dated 30 May 2024 before investing. To learn more about the Fund, visit aham.com.my.

- End of Press Release -

For media enquiries, please contact:

Lee Sheung Un | sheungun.lee@aham.com.my | +6017 296 3781

Wan Emi Muttalib | emi.muttalib@aham.com.my | +6010 231 8183

References

1. Source: FDA, as at 31 December 2023. Note: Includes drugs approved by CDER (Center for Drug Evaluation and Research).

About AHAM Asset Management Berhad

AHAM Asset Management Berhad ("AHAM Capital") is an institutionally-owned, independently managed asset and wealth management firm. Our purpose is clear. We are here to help our clients build wealth and achieve their financial goals through their trust.

Over the years, we have served the needs of corporates, institutions, pension funds, high net worth individuals and the mass affluent in building a stronger, more resilient financial future by delivering better investment outcomes and creating a positive impact.

Drawing upon years of expertise and experience, we invest into an array of asset classes including equities, fixed income, money market instruments, structured products, and other alternative assets to generate long-term sustainable returns. By adopting a holistic and client-centric approach, our wealth platform allows investors to gain access to regional and global solutions across multiple strategies in various asset classes.

Through a stable of unit trust funds, exchange-traded funds, Shariah-compliant and cash management solutions, we provide comprehensive solutions that help investors realise their financial goals. For private wealth & family offices, we also offer bespoke wealth management solutions including portfolio management and advisory which are tailored to achieve specific outcomes.

Embracing the same entrepreneurial ethos of the company since its founding, we are charting new frontiers in wealth through innovative and progressive solutions that empower investors in a changing world. These include spearheading digitalisation initiatives that would enhance client experience as well as make investing simpler and more accessible to everyone.

As a corporate citizen, we are committed to growing together sustainably with the communities we operate in by fostering greater financial inclusion as well as championing financial literacy.

Incorporated in Malaysia on 2 May 1997, AHAM Capital first began operations under the name Hwang-DBS Capital Berhad in 2001. On 29 July 2022, CVC Capital Partners ("CVC") a global private equity and investment advisory firm acquired an approximate 68.35% controlling interest in AHAM Capital via a private equity fund, i.e. CVC Capital Partners Asia V managed by CVC. AHAM Capital is also 27.0% owned by Nikko Asset Management International Limited, a wholly-owned subsidiary of Tokyo-based Nikko Asset Management Co. Ltd., an Asian investment management franchise. The remaining 4.65% are held by the key management personnel of AHAM Capital.

AHAM Capital's Shariah investment solutions are made available through its wholly owned subsidiary and Islamic investment arm, AIIMAN Asset Management Sdn. Bhd. ("AIIMAN").

Since its inception in 2001, AHAM Capital has achieved an exponential growth in its total assets under administration ("AUA"). As at 31 December 2023, the total Assets Under Administration (AUA) stood at approximately RM81.0 billion (combined of AHAM Capital and its subsidiaries, AIIMAN and Bintang Capital Partners). The AUA comprises of assets under management, investment advisory, and those under distribution.

Disclaimer

This content has been prepared by AHAM Asset Management Berhad ("AHAM Capital") (formerly known as Affin Hwang Asset Management Berhad) specific for its use, a specific target audience, and for discussion purposes only. All information contained within this presentation belongs to AHAM Capital and may not be copied, distributed, or otherwise disseminated in whole or in part without written consent of AHAM Capital. The information contained in this presentation may include, but is not limited to opinions, analysis, forecasts, projections, and expectations (collectively referred to as "Opinions"). Such information has been obtained from various sources including those in the public domain, are merely expressions of belief. Although this presentation has been prepared on the basis of information and/or Opinions that are believed to be correct at the time the presentation was prepared, AHAM Capital makes no expressed or implied warranty as to the accuracy and completeness of any such information and/or Opinions. As with any forms of financial products, the financial product mentioned herein (if any) carries with it various risks. Although attempts have been made to disclose all possible risks involved, the financial product may still be subject to inherent risk that may arise beyond our reasonable contemplation. The financial product may be wholly unsuited for you, if you are averse to the risk arising out of and/or in connection with the financial product. AHAM Capital is not acting as an advisor or agent to any person to whom this presentation is directed. Such persons must make their own independent assessments of the contents of this presentation, should not treat such content as advice relating to legal, accounting, taxation or investment matters and should consult their own advisers. AHAM Capital and its affiliates may act as a principal and agent in any transaction contemplated by this presentation, or any other transaction connected with any such transaction, and may as a result earn brokerage, commission, or other income. Nothing in this presentation is intended to be, or should be construed as an offer to buy or sell, or invitation to subscribe for, any securities. Neither AHAM Capital nor any of its directors, employees or representatives are to have any liability (including liability to any person by reason of negligence or negligent misstatement) from any statement, opinion, information, or matter (expressed or implied) arising out of, contained in or derived from or any omission from this presentation, except liability under statute that cannot be excluded.

Warning Statement

A copy of the Information Memorandum ("Info Memo"), Supplemental Info Memo (if any), and Product Highlights Sheet ("PHS") can be obtained at aham.com.my. Investors are advised to read and understand the contents of AHAM World Series – Biotechnology Fund (or the "Fund") Info Memo dated 30 May 2024, and the corresponding PHS before investing. There are fees and charges involved when investing

in the Fund. Investors are advised to consider and compare the fees and charges as well as the risks carefully before investing. Investors should make their own assessment of the risks involved in investing and should seek professional advice, where necessary. The price of units and distribution payable, if any, may go down as well as up and the past performance of the Fund should not be taken as indicative of its future performance. The Securities Commission Malaysia has not reviewed this material and takes no responsibilities for the contents of this material and expressly disclaims all liability, however arising from this material.